Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

71.65 +1.16 (+1.65%)
Streaming Delayed Price Updated: 12:08 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly... 
Via StockStory
News headline image
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast ↗
ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion. 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year... 
Via StockStory
News headline image
Where ANI Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
A Peek at ANI Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2025 ↗
 
Via Benzinga
News headline image
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential ↗
Piper Sandler has initiated coverage on ANI Pharmaceuticals, emphasizing its strategic shift towards high-margin brand assets, particularly the successful Cortrophin Gel, which has seen substantial... 
Via Benzinga
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire
News headline image
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Alimera Sciences (ALIM) Stock Up 77% Today? ↗
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals. 
Via InvestorPlace
News headline image
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal ↗
ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per share. The transaction is valued at $381 million and is expected to close... 
Via Benzinga
News headline image
ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
ANIP stock results show that ANI Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Alphabet, Dover And 2 Other Stocks Insiders Are Selling ↗
The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.